To conclude, our data support the administration of a booster dose of SARS-CoV-2 mRNA vaccine in patients with glomerular disease to ensure an effective immune response against SARS-CoV-2. Third, our cohort was heterogeneous: (i) 25% of patients had received anti-CD20 treatment in the 12 months prior to dose 3; (ii) all but 2 patients had B-cell reconstitution; and (iii) 9 of 32 patients actually had nephrotic syndrome at the time of dose 3. Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly effective in the healthy population but is less effective in immunocompromised patients such as patients with organ transplant, solid cancer, lymphoid malignancies or recent treatments with an anti-CD20 monoclonal antibody [[1], [3], [5], [7]]. [Extracted from the article]